aguilaroja
Member
- Joined
- Jul 24, 2013
- Messages
- 850
This research comes from a commercial spin-off of Maastricht University in the Nederlands. Authors in this group seem interested in vascular calcification. Here, the interest was in osteoblast-specific protein osteocalcin (OC)and metabolsim.. They chose to use a not-huge dose on MK-7 rather than menaquinone-4. The full data looks like the “good responders” had an average waist slimming effect of a bit over 2%, more than 1.5 cm. @haidut and others have described advantages of MK-4 in others threads.
Vitamin K-induced effects on body fat and weight: results from a 3-year vitamin K2 intervention study. - PubMed - NCBI
“In a randomized placebo-controlled human intervention trial, 214 postmenopausal women, 55-65 years of age, received either 180 mcg/day of vitamin K2 (menaquinone-7, MK-7) or placebo for 3 years.”
“In the total cohort, MK-7 supplementation increased circulating carboxylated OC (cOC) but had no effect on body composition. In those with an above-median response in OC carboxylation ('good responders'), MK-7 treatment resulted in a significant increase in total and human molecular weight adiponectin and a decrease in abdominal fat mass and in the estimated visceral adipose tissue area compared with the placebo group and the poor responders.”
Vitamin K-induced effects on body fat and weight: results from a 3-year vitamin K2 intervention study. - PubMed - NCBI
“In a randomized placebo-controlled human intervention trial, 214 postmenopausal women, 55-65 years of age, received either 180 mcg/day of vitamin K2 (menaquinone-7, MK-7) or placebo for 3 years.”
“In the total cohort, MK-7 supplementation increased circulating carboxylated OC (cOC) but had no effect on body composition. In those with an above-median response in OC carboxylation ('good responders'), MK-7 treatment resulted in a significant increase in total and human molecular weight adiponectin and a decrease in abdominal fat mass and in the estimated visceral adipose tissue area compared with the placebo group and the poor responders.”